Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology

J Nucl Cardiol. 2011 Feb;18(1):135-43. doi: 10.1007/s12350-010-9305-4.


With the rapid growth of molecular biology, in vivo imaging of such molecular process (i.e., molecular imaging) has been well developed. The molecular imaging has been focused on justifying advanced treatments and for assessing the treatment effects. Most of molecular imaging has been developed using PET camera and suitable PET radiopharmaceuticals. However, this technique cannot be widely available and we need alternative approach. ¹²³I-labeled compounds have been also suitable for molecular imaging using single-photon computed tomography (SPECT) ¹²³I-labeled meta-iodobenzylguanidine (MIBG) has been used for assessing severity of heart failure and prognosis. In addition, it has a potential role to predict fatal arrhythmia, particularly for those who had and are planned to receive implantable cardioverter-defibrillator treatment. ¹²³I-beta-methyl-iodophenylpentadecanoic acid (BMIPP) plays an important role for identifying ischemia at rest, based on the unique capability to represent persistent metabolic alteration after recovery of ischemia, so called ischemic memory. Since BMIPP abnormalities may represent severe ischemia or jeopardized myocardium, it may permit risk analysis in CAD patients, particularly for those with chronic kidney disease and/or hemodialysis patients. This review will discuss about recent development of these important iodinated compounds.

Publication types

  • Review

MeSH terms

  • 3-Iodobenzylguanidine*
  • Cardiology / trends
  • Cardiovascular Diseases / diagnostic imaging*
  • Fatty Acids*
  • Humans
  • Image Enhancement / methods*
  • Iodobenzenes*
  • Molecular Imaging / trends*
  • Nuclear Medicine / trends
  • Radionuclide Imaging / trends*
  • Radiopharmaceuticals


  • Fatty Acids
  • Iodobenzenes
  • Radiopharmaceuticals
  • iodofiltic acid
  • 3-Iodobenzylguanidine